Sign in
TerminatedPhase 1

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Chicago, Memphis, and New York, United StatesSee the 3 sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
4 people enrolled
Started
25 Aug 2020
Ended
6 Jan 2025
Type of study
Interventional
Treatments tested
  • OTQ923
Record updated
8 January 2026
Why it stopped
The decision of early termination was made due to business reasons and was not a consequence of any safety concern.

Who can take part

Age
2 years to 40 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Male or female subjects age 2-40 years inclusive
  • Confirmed diagnosis of sickle cell disease with globin typing (e.g. HbSS, HbSC, HbS/β0-thalassemia or others)
  • Performance status >70% (Karnofsky for subjects >16 years of age and Lansky for subjects <16 years of age)
  • At least one of the following indicators of disease severity as defined in the protocol - Vaso-occlusive pain crisis, Acute chest syndrome, Recurrent priapism, prior stroke, receive chronic transfusions, Red cell alloimmunization
  • Subjects, who have failed, not tolerated or refused hydroxyurea therapy

Who cannot take part

  • Prior HSCT or gene therapy
  • Clinically significant active infection
  • Seropositive for HIV or HTLV
  • Active known malignancy, myelodysplasia, abnormal cytogenetics or immunodeficiency
  • Known hepatic cirrhosis, bridging hepatic fibrosis or active hepatitis
  • Severe or progressive arteriopathy or cerebrovascular disease, including Moyamoya; Other protocol defined inclusion/exclusion criteria may apply
  • Available matched related donor for HSCT
  • Protocol defined iron overload
  • Cerebrovascular procedure within one year, including pial synangiosis for Moyamoya

Where in United States

  • University of ChicagoChicago, United States
  • St. Jude Children's Research HospitalMemphis, United States
  • Memorial Sloan Kettering Cancer CtrNew York, United States

About the trial

What the trial wants to find out

This study evaluated a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.

The group in the trial

  • OTQ923Treatment being tested

    Single intravenous infusion of OTQ923 Part A - Adults treated with OTQ923; Part B - Children age 2-17 treated with OTQ923 based on review of data from Part A by Health agency after a formal interim analysis.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease
Publications
Record updated
8 January 2026